Research Analysts Offer Predictions for SPRY FY2025 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities researchers at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($1.21) per share for the year, down from their previous forecast of ($1.02). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

A number of other analysts have also recently commented on the company. Raymond James upped their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price target for the company. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.00.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $13.15 on Wednesday. ARS Pharmaceuticals has a one year low of $7.55 and a one year high of $18.51. The business has a fifty day moving average price of $12.13 and a 200-day moving average price of $13.07. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -25.78 and a beta of 1.03.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $15.46 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bernard Wealth Management Corp. bought a new position in ARS Pharmaceuticals during the fourth quarter valued at $27,000. KLP Kapitalforvaltning AS bought a new stake in shares of ARS Pharmaceuticals in the 4th quarter worth about $73,000. BNP Paribas Financial Markets purchased a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at about $75,000. Ball & Co Wealth Management Inc. bought a new stake in ARS Pharmaceuticals during the fourth quarter worth approximately $105,000. Finally, Compass Capital Corp MA ADV purchased a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $106,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 49,600 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the completion of the transaction, the director now owns 210,346 shares in the company, valued at $2,357,978.66. This trade represents a 19.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now directly owns 7,696 shares in the company, valued at $107,744. This trade represents a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 159,600 shares of company stock valued at $1,866,516 in the last three months. 40.10% of the stock is currently owned by corporate insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.